Global R&D Pipeline
My Favorite
Hot Targets:
TIGIT
Back
Total number of drugs
125
Phase II and later clinical stages
12%
Involving companies
124
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YBL-012 | YBL-012 | Monoclonal antibody | Neoplasms | TIGIT inhibitors | YBiologics, Inc. | - | Discontinued (in Discovery) | - | - | - | - | - | - | - | - | - | YBL-012 | - | - | detail > | |
| Ori-Ab-007 | Ori-Ab-007 | Monoclonal antibody | Neoplasms | TIGIT inhibitors | OriCell Therapeutics Co.,Ltd. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | Ori-Ab-007 | - | - | detail > | |
| HH-101 | HH-101 | Monoclonal antibody | Neoplasms Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases Other Diseases | TIGIT inhibitors | Huahui Health Ltd. | - | Discontinued (in Phase 1) | Discontinued (in Phase 1) | - | - | - | - | - | - | - | - | HH-101 | - | - | detail > | |
| YBL-027 | YBL-027 | Bispecific antibody | Neoplasms | PDL1 inhibitors TIGIT inhibitors | YBiologics, Inc. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | YBL-027 | - | - | detail > | |
| B-267 | B-267 | Bispecific antibody | Neoplasms | TIGIT inhibitors ADCC T lymphocytes stimulants | FutureGen Biopharmaceutical (Beijing) Co., Ltd | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | B-267 | - | - | detail > | |
| B728 | B728 | Bispecific antibody | Neoplasms | PDL1 inhibitors TIGIT inhibitors ADCC Immunologic cytotoxicity Immunomodulators | FutureGen Biopharmaceutical (Beijing) Co., Ltd | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | B728 | - | - | detail > | |
| SL-VS9258 | SL-VS9258 | Fc fusion protein | Neoplasms | LIGHT inhibitors TIGIT inhibitors | Shattuck Labs, Inc. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | SL-VS9258 | - | - | detail > | |
| Ori-A611 | Ori-A611 | Monoclonal antibody | Neoplasms | TIGIT modulators | OriCell Therapeutics Co.,Ltd. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | Ori-A611 | - | - | detail > | |
| BAT-6021 | BAT-6021 | Monoclonal antibody | Neoplasms | TIGIT inhibitors | Bio-Thera Solutions, Ltd. | - | Discontinued (in Phase 1) | Discontinued (in Phase 1) | - | - | - | - | - | - | - | - | BAT-6021 | - | - | detail > | |
| PM-1024 | PM-1024 | Bispecific antibody | Neoplasms | CCR8 inhibitor TIGIT inhibitors | Biotheus, Inc. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | PM-1024 | - | - | detail > |
Total 125 data
1
2
3
4
5
6
...
12
13
